Full Press Release Details
Sanofi and Regeneron Report Positive Results With Alirocumab From Phase 2 Japanese Study.
REGN
Sanofi and Regeneron Report Positive Results With Alirocumab From Phase 2 Japanese Study
Key Takeaway: Sanofi and Regeneron Report Positive Results With Alirocumab From Phase 2 Japanese Study